期刊文献+

评中国成人2型糖尿病胰岛素促泌剂应用专家共识 被引量:5

Evaluation of the Expert Consensus on Insulin Secretagogues Application in Chinese Adults with Type 2 Diabetes
原文传递
导出
摘要 中国成人2型糖尿病的病理生理特点与欧美国家不同,其β细胞胰岛素分泌功能下降可能比胰岛素敏感性降低更明显。因此,中国成人2型糖尿病患者适合使用胰岛素促泌剂。为了强调其重要性,2012年4月在《中华内分泌代谢杂志》发表了《中国成人2型糖尿病胰岛素促泌剂应用的专家共识》,它对我国临床实践具有重要指导意义。本文重点评价了目前对胰岛素促泌剂认识的一些误区,比如低血糖、体重、β细胞功能及心血管安全性等问题。 The pathophysiologic characteristics of Chinese adults with type 2 diabetes(T2D) are different from those of patients from the European and American,reduction of insulin secretion function may be more severe compared to the decrease of insulin sensitivity.Therefore,insulin secretagogues are suitable for Chinese T2D.The expert consensus on insulin secretagogues application in Chinese adults with type 2 diabetes was published on Chinese Journal of Endocrinology and Metabolism in April 2012 and it is an important guidline for clinical practice in China.This paper focuses on evaluating some misunderstandings in the current knowledge of insulin secretagogues,such as hypoglycemia,weight,β cell function and cardiovascular safety etc.
作者 黄李 童南伟
出处 《临床药物治疗杂志》 2013年第1期42-44,共3页 Clinical Medication Journal
关键词 胰岛素促泌剂 2型糖尿病 磺脲类药物 insulin secretagogues type 2 diabetes sulfonylureas.
  • 相关文献

参考文献11

  • 1无,童南伟.中国成人2型糖尿病胰岛素促泌剂应用的专家共识[J].中华内分泌代谢杂志,2012,28(4):261-265. 被引量:41
  • 2童南伟.中国T2DM胰岛素促泌剂应用共识解读[N].中国医学论坛报2012:C10.
  • 3杨文英.磺脲类药物应用专家共识[J].国外医学(内分泌学分册),2004,24(4):255-259. 被引量:75
  • 4Schernthaner G,Grimaldi A,DiMario U, et al. GUIDE study:double-blind comparison of once-daily gliclazide MR and glimepiride in type2 diabetic patients [ J ] . Eur J Clin Invest, 2004, 34(8) : 535-542.
  • 5UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with Conventional treatment and risk of complications in patients with type2 diabetes(UKPDS33) [ J ] Lancet,1998,352 : 837-853.
  • 6ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [ J ] . N Engl J Med,2008, 358(24): 2560-2572.
  • 7Amiel SA,Dixon T,Mann R,et al.Hypoglycaemia in type 2 diabetes [ J ] . Diabet Med, 2008,25 (3): 248-249.
  • 8Pulizzi N.The place of sulfonylureas in the therapy far type 2 diabetes mellitus [ J ] . Metabolism,2006, 55(5 Suppl 1): 20-27.
  • 9The ORIGIN Trial Investigators.Basal insulin and cardiovascular and other outcomes in dysglycemia [ J ] . New Engl J Med,2012,367(4) : 319-328.
  • 10van Dieren S,Czernichow S,Chalmers J,et al.Weight changes and their predictors amongst 11140 patients with type 2 diabetes in the ADVANCE trail [ J ] .Diabetes Obesity Metab,2012,14(5) : 464-469.

二级参考文献19

  • 1杨文英.磺脲类药物应用专家共识[J].国外医学(内分泌学分册),2004,24(4):255-259. 被引量:75
  • 2贾伟平,陆俊茜,高鑫,邢惠莉,刘伟,刘志民,盛正妍,胡仁明,宁光,邹大进,冯波,项坤三.新诊断2型糖尿病患者一相胰岛素分泌和胰岛素敏感性评估[J].中华内分泌代谢杂志,2007,23(2):100-103. 被引量:32
  • 3Peter P, Frank R, Nick G, et al. Sulfonylurea stimulation of in aulin secretion. Diabetes, 2002,51 ( Suppl 3): S368-S376.
  • 4Garratt KN, Brady PA, Haasinger NL, et al. Sulfonylurea drugs increase early motality in patients with diabetes mellitus after direct angioplasty for acute myocardial infaction. J Am Cell Cardiol, 1999,33:119-124.
  • 5Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev,2000,21:585-618.
  • 6Davis TM, Parsons RW, Broadburst R J, et al. Arrhythmias and mortality after myocardial infaction in diabetic patients: relationship to diabetes treatment. Diabetes Care, 1998,21:637-640.
  • 7Renstrom E, Barg S, Thevenod F, et al. Sul.fonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K + channel-independent action. Diabetes, 2002,51 (Suppl 1 ): S33-S36.
  • 8Muller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic suffonylurea drug Amaryl. Mol Med, 2000,6:907-933.
  • 9Dills DG, Schneider J. Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res, 1996,28:426-429.
  • 10Muller G. Dynamics of plasma membrane microdomains and cross-talk to the insulin signalling cascade. FEBS Lett, 2002,531: 81-87.

共引文献109

同被引文献66

  • 1黄李,童南伟.2013美国内分泌医师协会糖尿病综合管理方案之血糖管理方案解读[J].中国医学前沿杂志(电子版),2013,5(8):36-39. 被引量:2
  • 2杨文英.磺脲类药物应用专家共识[J].国外医学(内分泌学分册),2004,24(4):255-259. 被引量:75
  • 3贾伟平,宁光,高鑫,严励,杨华章,李鸣,洪洁,陆志强,程桦,戚以勤,李忠文,项坤三.格列奇特缓释剂治疗2型糖尿病的多中心临床研究[J].中华医学杂志,2005,85(37):2636-2639. 被引量:19
  • 4邹豪,邵元福,朱才娟,邓渝林,马玉杰,陈盛新.医院药品DDD数排序分析的原理及利用[J].中国药房,1996,7(5):215-217. 被引量:1426
  • 5陈新谦,金有豫,汤光.新编药物学(17版)[M].北京:人民卫生出版社,2011:254.
  • 6中华医学会糖尿病学分会.2010版中国2型糖尿病防治指南2010版中国2型糖尿病防治指南[M].北京:北京大学医学出版社,2010:1-3.
  • 7Houlden R, Ross S, Harris S, et al. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: The Canadian INSIGHT study [ J ] . Diabetes Res Clin Pract, 2007, 78(2): 254-258.
  • 8Rosen stock J, Vico M, Wei L, et al. Effects of Dapagliflozin, an SGLT2 inhibitor, on HbAlc,body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on Pioglitazone monotherapy [ J ] .Diabetes Care, 2012, 35(7): 1473-1478.
  • 9杨宝峰.药理学[M].8版.北京:人民卫生出版社,2013:1-484.
  • 10American Diabetes Association Workgroup on Hypoglycemia.Defining and reporting hypoglycemia in diabetess[J]. Diabetes Care,2005, 28(5): 1245-1249.

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部